Royce & Associates LP decreased its position in Alumis Inc. (NASDAQ:ALMS – Free Report) by 63.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 193,041 shares of the company’s stock after selling 332,262 shares during the period. Royce & Associates LP’s holdings in Alumis were worth $1,427,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of ALMS. Pictet Asset Management Holding SA boosted its stake in shares of Alumis by 6,070.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 647,366 shares of the company’s stock worth $4,784,000 after acquiring an additional 636,875 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Alumis in the third quarter valued at approximately $49,000. Profund Advisors LLC increased its position in shares of Alumis by 1,010.4% in the third quarter. Profund Advisors LLC now owns 158,249 shares of the company’s stock valued at $1,169,000 after buying an additional 143,998 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Alumis by 20.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 23,617 shares of the company’s stock worth $172,000 after buying an additional 3,973 shares during the period. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Alumis during the 2nd quarter valued at approximately $33,000.
Insider Activity
In other Alumis news, Director Srinivas Akkaraju purchased 546,581 shares of Alumis stock in a transaction that occurred on Tuesday, September 8th. The stock was purchased at an average price of $10.63 per share, for a total transaction of $5,810,156.03. Following the transaction, the director directly owned 4,937,026 shares in the company, valued at $52,480,586.38. This trade represents a 12.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 99,754 shares of company stock worth $1,037,804 in the last 90 days. Company insiders own 33.70% of the company’s stock.
Alumis Trading Down 1.4%
Alumis stock opened at $4.33 on Friday. Alumis Inc. has a 52-week low of $4.22 and a 52-week high of $31.35. The company’s 50 day moving average is $6.79 and its two-hundred day moving average is $20.03.
Alumis (NASDAQ:ALMS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03. Alumis had a negative net margin of 5,844.54% and a negative return on equity of 89.77%. The business had revenue of $1.91 million for the quarter, compared to analyst estimates of $1.90 million. As a group, equities analysts forecast that Alumis Inc. will post -3.01 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
ALMS has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their price target on shares of Alumis from $25.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, November 13th. Guggenheim downgraded shares of Alumis from a “buy” rating to a “neutral” rating in a report on Thursday, September 3rd. Morgan Stanley dropped their target price on shares of Alumis from $39.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 2nd. Weiss Ratings raised shares of Alumis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, November 13th. Finally, Citigroup restated an “overweight” rating on shares of Alumis in a research report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.27.
View Our Latest Stock Analysis on Alumis
Alumis Profile
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
See Also
- Five stocks we like better than Alumis
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. (NASDAQ:ALMS – Free Report).
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
